Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Commentary · December 11, 2024

2024 Top Story in Oncology: Shifting the Scales — CDK4/6 Inhibitors and the Journey to Lower Recurrence Risk in Early-Stage Breast Cancer

Reshma Mahtani DO

 

 Save  Recommend
 Share

Additional Info

  1. Harbeck N, Rastogi P, O'Shaughnessy J, et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Paper presented at: 2023 ESMO Congress; October 20–24, 2023. Abstract LBA17.
  2. Goetz MP, Turner N, Sasano H, et al. Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). Paper presented at: 2023 ESMO Congress; October 20–24, 2023. Abstract 240MO.
  3. O’Shaughnessy J, Cicin I, Testa L, et al. 274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Paper presented at: 2023 ESMO Congress; October 20–24, 2023. Abstract 274P.
  4. Fasching PA, Stroyakovskiy D, Yardley D, et al. LBA13 - Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Paper presented at: 2024 ESMO Congress; September 13–17, 2024. Abstract LBA13.
  5. Loi, S, Stringer-reasor E, Frenel J, et al. 235MO - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE. Paper presented at: 2024 ESMO Congress; September 13–17, 2024. Abstract 235MO.
  6. Yardley DA, Untch M, Barrios Sr. CH, et al. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. Paper presented at: 2024 ASCO Annual Meeting; May 31–June 4, 2024. Abstract 512.

Disclosure statements are available on the authors' profiles:

Reshma Mahtani DO

Further Reading

Most Read This Week

Recently Updated